{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:25:09Z","timestamp":1791321909416,"version":"4.3.1"},"reference-count":110,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T00:00:00Z","timestamp":1581984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Analysis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jpha.2020.02.007","type":"journal-article","created":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T19:52:07Z","timestamp":1582055527000},"page":"522-531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Three-dimensional aspects of formulation excipients in drug discovery: a critical assessment on orphan excipients, matrix effects and drug interactions"],"prefix":"10.1016","volume":"10","author":[{"given":"Vijayabhaskar","family":"Veeravalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanumanth Srikanth","family":"Cheruvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratima","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Mohan","family":"Vamsi Madgula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpha.2020.02.007_bib1","first-page":"67","article-title":"The central role of excipients in drug formulation","volume":"18","author":"Pascal","year":"2013","journal-title":"Eur. Pharm. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.18773\/austprescr.2011.060","article-title":"Pharmaceutical Excipient \u2013 where do we begin","volume":"34","author":"Alison","year":"2011","journal-title":"Aust. Prescr."},{"key":"10.1016\/j.jpha.2020.02.007_bib3","first-page":"56","article-title":"Review of current issues in pharmaceutical excipients","volume":"31","author":"Dorothy","year":"2007","journal-title":"Pharmaceut. Technol."},{"key":"10.1016\/j.jpha.2020.02.007_bib4","article-title":"Global regulatory perspective of bulk pharmaceutical excipients","volume":"8","author":"Pramod","year":"2010","journal-title":"Pharm. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib5","series-title":"Encyclopedia of Pharmaceutical Technology","author":"Patrick","year":"2007"},{"key":"10.1016\/j.jpha.2020.02.007_bib6","series-title":"Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems","author":"Katdare","year":"2006"},{"key":"10.1016\/j.jpha.2020.02.007_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0014-827X(03)00079-X","article-title":"The safety of pharmaceutical excipients","volume":"58","author":"Pifferi","year":"2003","journal-title":"Farmaco"},{"key":"10.1016\/j.jpha.2020.02.007_bib8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jps.2600791123","article-title":"Pharmaceutical dosage forms: tablets. Vol. 1","volume":"79","author":"Sunil","year":"1990","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib9","series-title":"Excipient Development for Pharmaceutical, Biotechnology, and Drug Delivery Systems","first-page":"197","article-title":"Excipients for semisolid formulations","author":"Srivastava","year":"2006"},{"key":"10.1016\/j.jpha.2020.02.007_bib10","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S1044-0305(96)00289-9","article-title":"Quantification of a potent 5-HT2a antagonist and an active metabolite in rat plasma and brain microdialysate by liquid chromatography-tandem mass spectrometry","volume":"8","author":"Heath","year":"1997","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1097-0231(19970115)11:1<17::AID-RCM812>3.0.CO;2-N","article-title":"The simultaneous determination of mixtures of drug candidates by liquid chromatography\/atmospheric pressure chemical ionization mass spectrometry as an in\u00a0vivo drug screening procedure","volume":"11","author":"Olah","year":"1997","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib12","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1021\/ac9906633","article-title":"Higher throughput bioanalysis by automation of a protein precipitation assay using a 96-well format with detection by LC-MS\/MS","volume":"72","author":"Watt","year":"2000","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib13","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1021\/ac00125a022","article-title":"High-speed liquid chromatography\/tandem mass spectrometry for the determination of drugs in biological samples","volume":"58","author":"Covey","year":"1986","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib14","series-title":"Tandem Mass Spectrometry-Applications and Principles","article-title":"Identifying and overcoming matrix effects in drug discovery and development","author":"Hall","year":"2012"},{"key":"10.1016\/j.jpha.2020.02.007_bib15","series-title":"Drug\u2013Drug Interactions: Part One (Small Molecule Drugs), FDA\u2019s Drug Review Process and the Package Label","first-page":"255","author":"Brody","year":"2018"},{"key":"10.1016\/j.jpha.2020.02.007_bib16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/0973-8398.154688","article-title":"Influence of excipients on drug absorption via modulation of intestinal transporters activity","volume":"9","author":"Thakkar","year":"2015","journal-title":"Asian J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib17","series-title":"Drug Metabolism Handbook: Concepts and Applications","author":"Nassar","year":"2009"},{"key":"10.1016\/j.jpha.2020.02.007_bib18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s11596-010-0543-0","article-title":"Inhibitive effect of cremophor RH40 or tween 80-based self-microemulsiflying drug delivery system on cytochrome P450 3A enzymes in murine hepatocytes","volume":"30","author":"Rao","year":"2010","journal-title":"J.\u00a0Huazhong Univ. Sci. Tech. Med. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib19","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/mp3001815","article-title":"Pharmaceutical excipients influence the function of human uptake transporting proteins","volume":"9","author":"Engel","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S0009-9236(03)00010-9","article-title":"\u201cInactive\u201d excipients such as Cremophor can affect in\u00a0vivo drug disposition","volume":"73","author":"Wandel","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpha.2020.02.007_bib21","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ejps.2008.11.002","article-title":"Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in\u00a0vitro and in\u00a0vivo","volume":"36","author":"Ren","year":"2009","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib22","first-page":"319","article-title":"Lipid excipients Peceol and Gelucire 44\/14 decrease P-glycoprotein mediated efflux of rhodamine 123 partially due to modifying P-glycoprotein protein expression within Caco-2 cells","volume":"10","author":"Sachs-Barrable","year":"2007","journal-title":"J.\u00a0Pharm. Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejps.2015.12.018","article-title":"Pharmaceutical excipients - quality, regulatory and biopharmaceutical considerations","volume":"87","author":"Elder","year":"2016","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib24","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.xphs.2016.12.002","article-title":"Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options","volume":"106","author":"Aungst","year":"2017","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0378-5173(94)90271-2","article-title":"Self-emulsifying drug delivery systems (SEDDS) with polyglycolyzed glycerides for improving in\u00a0vitro dissolution and oral absorption of lipophilic drugs","volume":"106","author":"Shah","year":"1994","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0169-409X(96)00494-2","article-title":"Lipid-based vehicles for the oral delivery of poorly water soluble drugs","volume":"25","author":"Humberstone","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib28","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrd2197","article-title":"Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs","volume":"6","author":"Porter","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jpha.2020.02.007_bib29","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijpharm.2007.05.006","article-title":"Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design","volume":"342","author":"Vandecruys","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib30","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1002\/jps.24199","article-title":"Oral delivery of highly lipophilic poorly water-soluble drugs: spray-dried dispersions to improve oral absorption and enable high-dose toxicology studies of a P2Y1 antagonist","volume":"103","author":"Chen","year":"2014","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0378-5173(95)00122-Y","article-title":"Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs","volume":"125","author":"Liversidge","year":"1995","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0928-0987(02)00251-8","article-title":"Nanosizing: a formulation approach for poorly-water-soluble compounds","volume":"18","author":"Merisko-Liversidge","year":"2003","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib33","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1248\/cpb.c14-00232","article-title":"Practical method for preparing nanosuspension formulations for toxicology studies in the discovery stage: formulation optimization and in\u00a0vitro\/in\u00a0vivo evaluation of nanosized poorly water-soluble compounds","volume":"62","author":"Komasaka","year":"2014","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.jpha.2020.02.007_bib34","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2011.07.003","article-title":"Recent advances and novel strategies in pre-clinical formulation development: an overview","volume":"156","author":"Shah","year":"2011","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.jpha.2020.02.007_bib36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.15415\/jptrm.2013.11006","article-title":"Modified excipients in novel drug delivery: need of the day","volume":"1","author":"Kanojia","year":"2013","journal-title":"J.\u00a0Pharm. Tech. Res. Manag."},{"key":"10.1016\/j.jpha.2020.02.007_bib37","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1517\/17425255.2.5.715","article-title":"Preclinical formulations for discovery and toxicology: physicochemical challenges","volume":"2","author":"Neervannan","year":"2006","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.jpha.2020.02.007_bib38","series-title":"Handbook of Pharmaceutical Excipients","author":"Rowe","year":"2006"},{"key":"10.1016\/j.jpha.2020.02.007_bib39","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3163\/1536-5050.100.1.018","article-title":"Martindale: the complete drug reference. 37th ed.","volume":"100","author":"Wisher","year":"2012","journal-title":"J.\u00a0Med. Libr. Assoc."},{"key":"10.1016\/j.jpha.2020.02.007_bib41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0378-5173(01)00701-3","article-title":"The effect of \u03b1-tocopherol on the in\u00a0vitro solubilisation of lipophilic drugs","volume":"222","author":"Nielsen","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib42","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.addr.2003.12.005","article-title":"Tocol emulsions for drug solubilization and parenteral delivery","volume":"56","author":"Constantinides","year":"2004","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib43","series-title":"Handbook of Fillers, Extenders, and Diluents","author":"Ash","year":"2007"},{"key":"10.1016\/j.jpha.2020.02.007_bib44","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/BF02976716","article-title":"Fluorescence spectroscopy studies on micellization of poloxamer 407 solution","volume":"26","author":"Lee","year":"2003","journal-title":"Arch Pharm. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib45","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.jcis.2005.06.013","article-title":"Concentration, temperature, and salt-induced micellization of a triblock copolymer Pluronic L64 in aqueous media","volume":"292","author":"Mata","year":"2005","journal-title":"J.\u00a0Colloid Interface Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib46","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/pi.1935","article-title":"Aggregation behaviour of Pluronic\u00ae L64 surfactant at various temperatures and concentrations examined by dynamic light scattering and viscosity measurements","volume":"55","author":"Jebari","year":"2006","journal-title":"Polym. Int."},{"key":"10.1016\/j.jpha.2020.02.007_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/03639040500390934","article-title":"Development of a thermogelling ophthalmic formulation of cysteine","volume":"32","author":"Dumortier","year":"2006","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib48","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ijpharm.2006.12.038","article-title":"Development of a poloxamer analogs\/carbopol-based in situ gelling and mucoadhesive ophthalmic delivery system for puerarin","volume":"337","author":"Qi","year":"2007","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.fertnstert.2004.09.024","article-title":"Evaluation of a novel vaginal bromocriptine mesylate formulation: a pilot study","volume":"83","author":"Darwish","year":"2005","journal-title":"Fertil. Steril."},{"key":"10.1016\/j.jpha.2020.02.007_bib50","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/10717540500316003","article-title":"Thermally reversible in situ gelling carbamazepine liquid suppository","volume":"13","author":"El-Kamel","year":"2006","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jpha.2020.02.007_bib51","doi-asserted-by":"crossref","first-page":"7541","DOI":"10.1158\/0008-5472.CAN-05-1112","article-title":"A\u00a0novel method for viral gene delivery in solid tumors","volume":"65","author":"Wang","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijpharm.2004.03.001","article-title":"Impact of excipients on the absorption of P-glycoprotein substrates in\u00a0vitro and in\u00a0vivo","volume":"278","author":"Cornaire","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib53","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/10915810600961531","article-title":"Nonclinical vehicle use in studies by multiple routes in multiple species","volume":"25","author":"Gad","year":"2006","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.jpha.2020.02.007_bib55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.vascn.2006.10.002","article-title":"Tracking problems and possible solutions in the quantitative determination of small molecule drugs and metabolites in biological fluids using liquid chromatography\u2013mass spectrometry","volume":"55","author":"Bakhtiar","year":"2007","journal-title":"J.\u00a0Pharmacol. Toxicol. Methods"},{"key":"10.1016\/j.jpha.2020.02.007_bib56","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.4155\/bio.09.117","article-title":"Matrix effect elimination during LC\u2013MS\/MS bioanalytical method development","volume":"1","author":"C\u00f4t\u00e9","year":"2009","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpha.2020.02.007_bib57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/mas.20298","article-title":"An overview of matrix effects in liquid chromatography\u2013mass spectrometry","volume":"30","author":"Trufelli","year":"2011","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib58","first-page":"48","article-title":"Identification and reduction of matrix effects caused by polyethylene glycol 400 in bioanalysis using liquid chromatography\/tandem mass spectrometry","volume":"3","author":"Vijaya Bhaskar","year":"2013","journal-title":"Int. J. Pharm. Innov."},{"key":"10.1016\/j.jpha.2020.02.007_bib59","first-page":"1","article-title":"Identification and reduction of matrix effects caused by cremophor EL in bioanalysis using liquid chromatography\/tandem mass spectrometry","volume":"4","author":"Vijaya Bhaskar","year":"2013","journal-title":"J.\u00a0Anal. Bioanal. Tech."},{"key":"10.1016\/j.jpha.2020.02.007_bib60","first-page":"166","article-title":"Identification and reduction of matrix effects caused by solutol Hs15 in bioanalysis using liquid chromatography\/tandem mass spectrometry","volume":"4","author":"Vijaya Bhaskar","year":"2013","journal-title":"J.\u00a0Anal. Bioanal. Tech."},{"key":"10.1016\/j.jpha.2020.02.007_bib61","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jchromb.2006.02.011","article-title":"Liquid chromatography\u2013mass spectrometry\/mass spectrometry method development for drug metabolism studies: examining lipid matrix ionization effects in plasma","volume":"833","author":"Little","year":"2006","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.jpha.2020.02.007_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1039\/b209521c","article-title":"Internal standard signal suppression by co-eluting analyte in isotope dilution LC-ESI-MS","volume":"128","author":"Sojo","year":"2003","journal-title":"Analyst"},{"key":"10.1016\/j.jpha.2020.02.007_bib63","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1021\/ac025988p","article-title":"Effect of signal interference from dosing excipients on pharmacokinetic screening of drug candidates by liquid chromatography\/mass spectrometry","volume":"74","author":"Tong","year":"2002","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib64","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/rcm.951","article-title":"Post-column infusion study of the \u2018dosing vehicle effect\u2019in the liquid chromatography\/tandem mass spectrometric analysis of discovery pharmacokinetic samples","volume":"17","author":"Shou","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib65","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/rcm.1139","article-title":"Matrix effects during analysis of plasma samples by electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their elimination","volume":"17","author":"Schuhmacher","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/rcm.1276","article-title":"A\u00a0study of ion suppression effects in electrospray ionization from mobile phase additives and solid-phase extracts","volume":"18","author":"Mallet","year":"2004","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib67","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/rcm.876","article-title":"Investigation of matrix effects in bioanalytical high-performance liquid chromatography\/tandem mass spectrometric assays: application to drug discovery","volume":"17","author":"Mei","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib68","first-page":"92","article-title":"Implications of matrix effects in ultra-fast gradient or fast isocratic liquid chromatography with mass spectrometry in drug discovery, Rapid Commun","volume":"16","author":"Tiller","year":"2002","journal-title":"Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/135613","article-title":"Liquid chromatography\/tandem mass spectrometry method for quantitation of Cremophor EL and its applications","author":"Vijaya Bhaskar","year":"2013","journal-title":"Int. J. Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib70","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jpha.2014.09.002","article-title":"Liquid chromatography\/tandem mass spectrometry method for quantitative estimation of solutol HS15 and its applications","volume":"5","author":"Vijaya Bhaskar","year":"2015","journal-title":"J.\u00a0Pharm. Anal."},{"key":"10.1016\/j.jpha.2020.02.007_bib71","first-page":"163","article-title":"Determination of cremophor EL in rat plasma by LC-MS\/MS: application to a pharmacokinetic study","volume":"4","author":"Vijaya Bhaskar","year":"2013","journal-title":"J.\u00a0Anal. Bioanal. Tech."},{"key":"10.1016\/j.jpha.2020.02.007_bib72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jchromb.2013.02.021","article-title":"Liquid chromatography\/tandem mass spectrometry method for quantitative estimation of polyethylene glycol 400 and its applications","volume":"926","author":"Vijaya Bhaskar","year":"2013","journal-title":"J.\u00a0Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib73","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1002\/rcm.2102","article-title":"A\u00a0study of common discovery dosing formulation components and their potential for causing time-dependent matrix effects in high-performance liquid chromatography tandem mass spectrometry assays","volume":"19","author":"Xu","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib74","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jpba.2005.03.009","article-title":"Ion-suppression effects in liquid chromatography\u2013tandem mass spectrometry due to a formulation agent, a case study in drug discovery bioanalysis","volume":"39","author":"Larger","year":"2005","journal-title":"J.\u00a0Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.jpha.2020.02.007_bib75","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.4155\/bio.13.201","article-title":"Case studies: the impact of nonanalyte components on LC\u2013MS\/MS-based bioanalysis: strategies for identifying and overcoming matrix effects","volume":"5","author":"Li","year":"2013","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpha.2020.02.007_bib76","first-page":"2559","article-title":"Identification and reduction of ion suppression effects on pharmacokinetic parameters by polyethylene glycol 400, Rapid Commun","volume":"20","author":"Weaver","year":"2006","journal-title":"Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib77","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4155\/bio.12.82","article-title":"Perspectives on addressing ionization matrix effects in LC\u2013MS bioanalysis","volume":"4","author":"Liang","year":"2012","journal-title":"Bioanalysis"},{"key":"10.1016\/j.jpha.2020.02.007_bib78","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1044-0305(00)00163-X","article-title":"Mechanistic investigation of ionization suppression in electrospray ionization","volume":"11","author":"King","year":"2000","journal-title":"J.\u00a0Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib79","series-title":"Guidance for Industry: Bioanalytical Method Validation","author":"US Food and Drug Administration","year":"2001"},{"key":"10.1016\/j.jpha.2020.02.007_bib80","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC\u2212 MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/1096-9888(200007)35:7<763::AID-JMS16>3.0.CO;2-#","article-title":"Some tenets pertaining to electrospray ionization mass spectrometry","volume":"35","author":"Cole","year":"2000","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib82","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1021\/ac00072a020","article-title":"Dependence of ion intensity in electrospray mass spectrometry on the concentration of the analytes in the electrosprayed solution","volume":"65","author":"Tang","year":"1993","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib83","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mas.20247","article-title":"Electrospray: from ions in solution to ions in the gas phase, what we know now","volume":"28","author":"Kebarle","year":"2009","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib84","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1021\/ac970095w","article-title":"A\u00a0predictive model for matrix and analyte effects in electrospray ionization of singly-charged ionic analytes","volume":"69","author":"Enke","year":"1997","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib85","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1021\/ac00208a012","article-title":"Investigations of the electrospray interface for liquid chromatography\/mass spectrometry","volume":"62","author":"Ikonomou","year":"1990","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpha.2020.02.007_bib86","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0003-2670(99)00600-5","article-title":"Challenges in achieving a fundamental model for ESI","volume":"406","author":"Constantopoulos","year":"2000","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jpha.2020.02.007_bib87","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1002\/(SICI)1097-0231(19990630)13:12<1175::AID-RCM639>3.0.CO;2-0","article-title":"The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds","volume":"13","author":"Bonfiglio","year":"1999","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib88","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0021-9673(95)00175-M","article-title":"Enhanced sensitivity for peptide mapping with electrospray liquid chromatography-mass spectrometry in the presence of signal suppression due to trifluoroacetic acid-containing mobile phases","volume":"712","author":"Apffel","year":"1995","journal-title":"J.\u00a0Chromatogr. A"},{"key":"10.1016\/j.jpha.2020.02.007_bib89","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/1096-9888(200007)35:7<784::AID-JMS17>3.0.CO;2-Q","article-title":"Importance of gas-phase proton affinities in determining the electrospray ionization response for analytes and solvents","volume":"35","author":"Amad","year":"2000","journal-title":"J.\u00a0Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib90","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/mas.10008","article-title":"Practical implications of some recent studies in electrospray ionization fundamentals","volume":"20","author":"Cech","year":"2001","journal-title":"Mass Spectrom. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib91","series-title":"52nd ASMS Conference on Mass Spectrometry","article-title":"Overcoming matrix effects resulting from biological phospholipids through selective extractions in quantitative LC\/MS\/MS","author":"Bennett","year":"2004"},{"key":"10.1016\/j.jpha.2020.02.007_bib92","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchromb.2006.12.030","article-title":"Systematic and comprehensive strategy for reducing matrix effects in LC\/MS\/MS analyses","volume":"852","author":"Chambers","year":"2007","journal-title":"J.\u00a0Chromatogr. B"},{"key":"10.1016\/j.jpha.2020.02.007_bib93","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/rcm.908","article-title":"Ion suppression in the determination of clenbuterol in urine by solid-phase extraction atmospheric pressure chemical ionisation ion-trap mass spectrometry","volume":"17","author":"Van Hout","year":"2003","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.jpha.2020.02.007_bib94","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.chroma.2004.05.056","article-title":"Simultaneous determination of fluoroquinolone, sulfonamide, and trimethoprim antibiotics in wastewater using tandem solid phase extraction and liquid chromatography\u2013electrospray mass spectrometry","volume":"1042","author":"Renew","year":"2004","journal-title":"J.\u00a0Chromatogr. A"},{"key":"10.1016\/j.jpha.2020.02.007_bib95","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1002\/jps.10176","article-title":"A\u00a0comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in\u00a0vitro","volume":"91","author":"Hugger","year":"2002","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib96","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1023\/A:1015000503629","article-title":"Inhibition of P-glycoprotein by D-\u03b1-tocopheryl polyethylene glycol 1000 succinate (TPGS)","volume":"16","author":"Dintaman","year":"1999","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib97","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/(SICI)1097-0215(19961009)68:2<245::AID-IJC18>3.0.CO;2-9","article-title":"Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid-polyethylene glycol-fatty acid diesters, novel inhibitors of P-glycoprotein function","volume":"68","author":"Komarov","year":"1996","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.jpha.2020.02.007_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0168-3659(02)00419-4","article-title":"Effects of polyether-modified poly (acrylic acid) microgels on doxorubicin transport in human intestinal epithelial Caco-2 cell layers","volume":"88","author":"Bromberg","year":"2003","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.jpha.2020.02.007_bib99","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00001813-199810000-00011","article-title":"Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice","volume":"9","author":"Badary","year":"1998","journal-title":"Anti Canc. Drugs"},{"key":"10.1016\/j.jpha.2020.02.007_bib100","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1002\/jps.20183","article-title":"Determination of P-glycoprotein inhibition by excipients and their combinations using an integrated high-throughput process","volume":"93","author":"Wang","year":"2004","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib101","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdd.383","article-title":"In\u00a0vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam","volume":"25","author":"Bravo Gonz\u00e1lez","year":"2004","journal-title":"Biopharm Drug Dispos."},{"key":"10.1016\/j.jpha.2020.02.007_bib102","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jps.1127","article-title":"Effect of common excipients on Caco-2 transport of low-permeability drugs","volume":"90","author":"Bhagwant","year":"2001","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib103","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jps.2600810908","article-title":"Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells","volume":"81","author":"Anderberg","year":"1992","journal-title":"J.\u00a0Pharmaceut. Sci."},{"key":"10.1016\/j.jpha.2020.02.007_bib104","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1136\/gut.19.2.103","article-title":"Direct effect of bile salts and phospholipids on the physical properties of mucus","volume":"19","author":"Martin","year":"1978","journal-title":"Gut"},{"key":"10.1016\/j.jpha.2020.02.007_bib105","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1023\/A:1015992819290","article-title":"Enhancement of colonic drug absorption by the transcellular permeation route","volume":"5","author":"Tomita","year":"1988","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib106","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ijpharm.2008.12.005","article-title":"Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients","volume":"370","author":"Yamagata","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib107","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/0006-2952(92)90141-5","article-title":"Modulation of the levels of cytochromes P450 in rat liver and lung by dietary lipid","volume":"43","author":"Yoo","year":"1992","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpha.2020.02.007_bib108","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.addr.2007.08.017","article-title":"The effects of pharmaceutical excipients on drug disposition","volume":"59","author":"Buggins","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jpha.2020.02.007_bib109","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1021\/mp400175n","article-title":"Mediation of in\u00a0vitro cytochrome P450 activity by common pharmaceutical excipients","volume":"10","author":"Martin","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jpha.2020.02.007_bib110","article-title":"In\u00a0vitro evaluation of the inhibitory potential of pharmaceutical excipients on human carboxylesterase 1A and 2","volume":"9","author":"Zhang","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.jpha.2020.02.007_bib111","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s11095-010-0170-2","article-title":"Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells","volume":"27","author":"Tompkins","year":"2010","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpha.2020.02.007_bib112","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ejpb.2008.03.019","article-title":"Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration","volume":"70","author":"Ren","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."}],"container-title":["Journal of Pharmaceutical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177919307749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2095177919307749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:31:32Z","timestamp":1761859892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2095177919307749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":110,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S2095177919307749"],"URL":"https:\/\/doi.org\/10.1016\/j.jpha.2020.02.007","relation":{},"ISSN":["2095-1779"],"issn-type":[{"value":"2095-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three-dimensional aspects of formulation excipients in drug discovery: a critical assessment on orphan excipients, matrix effects and drug interactions","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpha.2020.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Xi'an Jiaotong University. Production and hosting by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}